I have already answered this question, but the most important...

I have already answered this question, but the most important thing to keep in mind with RC220 bisantrene is we are not trying to replace the current anthracyclines, but make them work better, and most importantly, safer to use. The currently used anthracyclines like doxorubicin are amazingly effectively anticancer agents, but they are not able to be used to the full potential due to their inherent cardiotoxicity. What we are trying to do is allow the current anthracycline to be used to their full potential by protecting the heart while adding additional anticancer activity.

All the historical and current data suggest that annamycin is clinically inferior to doxorubicin. No doctor is going to shift to a less effective experimental drug if they can keep using what they know works without the cardiovascular toxicity that limits the use of anthracyclines like doxorubicin.